Bladder cancer diagnostics startup floatbio raises $148K from MYSC
What's the deal? South Korean diagnostics startup floatbioDealroom has a profile for this one. Try Dealroom → has raised about US$167.7K (roughly $148,000) from MYSCDealroom has a profile for this one. Try Dealroom → (엠와이소셜컴퍼니), the company said. The investment runs through the KAIST-MYSC Double Impact FundDealroom has a profile for this one. Try Dealroom →.
Why now? floatbio was selected through MYSC's in-house investment batch program, "2026 EMA Original." It is now preparing clinical trials and regulatory approval while building out mass, uniform production and quality-control systems.
What's the endgame? The company develops diagnostic kits using a platform that amplifies faint signals from enzyme biomarkers. Its first product, BLOOM, is a point-of-care in-vitro kit that screens for bladder cancer from urine, designed to cut signal interference from blood and other impurities.
In a double-blind investigator trial at Korea University Anam Hospital using 105 clinical urine samples, BLOOM confirmed its bladder cancer detection performance. The results were published in Nature Biomedical Engineering .
floatbio plans to apply BLOOM first to bladder cancer, then expand to conditions such as periodontal disease. It is also pursuing a phase-change-based high-sensitivity technology, "Cut & Dip," to reach diseases requiring multiple-biomarker analysis, such as pancreatic cancer.
What they're saying: Chief executive officer Jung Young-do said the company wants to refine BLOOM so "more patients can conveniently get tested," and over the long term expand the technology to point-of-care diagnostics for various diseases (translated from Korean).
MYSC analyst Park Jung-ho said floatbio is building "a point-of-care solution that can improve access to bladder cancer diagnosis" and that the firm will support clinical, regulatory, and production work while reviewing follow-on pipeline expansion (translated from Korean).
The signal: The round is small, but its structure through an impact fund signals investor appetite for research-backed diagnostics that lower the cost and complexity of cancer screening.
Read more: wowtale.net
Image credit: Generated with Gemini
